Sangamo Therapeutics (SGMO) Projected to Post Quarterly Earnings on Monday

Sangamo Therapeutics (NASDAQ:SGMO) is projected to release its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect Sangamo Therapeutics to post earnings of $0.01 per share and revenue of $40.25 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:00 PM ET.

Sangamo Therapeutics Stock Down 4.5%

SGMO stock opened at $0.38 on Friday. The firm has a market capitalization of $127.26 million, a PE ratio of -0.86 and a beta of 1.33. Sangamo Therapeutics has a twelve month low of $0.35 and a twelve month high of $1.04. The stock’s 50 day moving average is $0.41 and its 200-day moving average is $0.49.

Institutional Trading of Sangamo Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers bought a new stake in Sangamo Therapeutics in the fourth quarter worth about $31,000. XTX Topco Ltd bought a new position in shares of Sangamo Therapeutics during the 2nd quarter valued at approximately $41,000. State of Wyoming purchased a new stake in shares of Sangamo Therapeutics during the 4th quarter worth approximately $47,000. Engineers Gate Manager LP increased its stake in shares of Sangamo Therapeutics by 101.7% during the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 44,078 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Sangamo Therapeutics in the 4th quarter worth approximately $56,000. Hedge funds and other institutional investors own 56.92% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on SGMO shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, February 10th. Wall Street Zen cut shares of Sangamo Therapeutics to a “strong sell” rating in a research report on Saturday, January 31st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Sangamo Therapeutics presently has a consensus rating of “Hold” and an average target price of $4.33.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.